Breakthrough drug trial aims to help kids with dwarfism grow taller

NCT ID NCT06164951

Completed Disease control Sponsor: QED Therapeutics, a BridgeBio company Source: ClinicalTrials.gov ↗

Summary

This Phase 3 study tested whether the drug infigratinib could help children with achondroplasia (the most common form of dwarfism) grow faster. The trial involved 114 children and teenagers aged 3 to 18 who took either the drug or a placebo. Researchers measured changes in height, body proportions, and overall health to see if the treatment was effective and safe.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

QED Investigative Site

San Francisco, California, 94609, United States
QED Investigative Site

Aurora, Colorado, 80045, United States
QED Investigative Site

Baltimore, Maryland, 21287, United States
QED Investigative Site

Columbia, Missouri, 65212, United States
QED Investigative Site

Cincinnati, Ohio, 45229, United States
QED Investigative Site

Nashville, Tennessee, 37232, United States
QED Investigative Site

Madison, Wisconsin, 53792, United States
QED Investigative Site

Buenos Aires, Buenos Aires F.D., C1245AAM, Argentina
QED Investigative Site

Parkville, Victoria, 3052, Australia
QED Investigative Site

Edmonton, Alberta, T6G 2B7, Canada
QED Investigative Site

London, Ontario, N6A 5W9, Canada
QED Investigative Site

Ottawa, Ontario, K1H 8L1, Canada
QED Investigative Site

Montreal, Quebec, H3T 1C5, Canada
QED Investigative Site

Bron, 69677, France
QED Investigative Site

Paris, 75015, France
QED Investigative Site

Toulouse, 31059, France
QED Investigative Site

Rome, 00168, Italy
QED Investigative Site

Bergen, 5009, Norway
QED Investigative Site

Oslo, 0372, Norway
QED Investigative Site

Singapore, 229899, Singapore
QED Investigative Site

Málaga, 29010, Spain
QED Investigative Site

Vitoria-Gasteiz, 01008, Spain
QED Investigative Site

Bristol, BS2 8BJ, United Kingdom
QED Investigative Site

Glasgow, G51 4TF, United Kingdom
QED Investigative Site

London, SE1 7EH, United Kingdom
QED Investigative Site

Manchester, M13 9WL, United Kingdom
QED Investigative Site

Sheffield, S10 2TH, United Kingdom

Conditions

Explore the condition pages connected to this study.

ACHONDROPLASIA